Investigating Birth and Thyroid Outcomes of Maternal-Fetal Environmental Exposures (IBM-E): A Cohort Protocol for Dietary Iodine and Endocrine Disruptors
Article information
Abstract
Background
Endocrine-disrupting chemicals (EDCs) are environmental pollutants that may impair maternal and fetal health by disrupting hormonal systems, including the thyroid. Both iodine deficiency and excess are associated with thyroid dysfunction and adverse obstetrical outcomes. However, the combined impacts of EDCs and iodine exposure on maternal-fetal thyroid homeostasis remain undetermined. We established the Investigating Birth and Thyroid Outcomes of Maternal-Fetal Environmental Exposures (IBM-E) cohort to prospectively assess the effects of maternal exposures to dietary iodine and EDCs on thyroid function, pregnancy complications, and offspring growth and development.
Methods
In this prospective observational study, we aim to enroll 556 pregnant women between 2024 and 2027 at a tertiary hospital in Korea. Maternal blood and urine samples will be collected at six time points, spanning from early pregnancy through 15 months postpartum, with infant samples collected at three time points. EDCs will be quantified using ultra-high performance liquid chromatography-tandem mass spectrometry. Thyroid function and urinary iodine concentration will be measured in both mothers and infants.
Results
As of the current interim analyses of 193 mothers and 229 neonates, 15.0% of mothers had thyroid dysfunction and 11.4% developed preeclampsia. Preterm birth occurred in 23.8% of cases, and 16.6% of neonates were small for gestational age.
Conclusion
The IBM-E cohort is designed to enable the longitudinal assessment of gestational environmental exposures and their potential impacts on maternal and fetal thyroid function, as well as pregnancy and neonatal outcomes. The findings of this study may inform preventive strategies and guide policy development in perinatal environmental health.
INTRODUCTION
Environmental exposures during pregnancy, including synthetic chemicals and essential micronutrients, are increasingly recognized as critical determinants of maternal and fetal health. Among these, the World Health Organization characterizes endocrine-disrupting chemicals (EDCs) as exogenous substances capable of altering endocrine system function and causing adverse health effects in both mothers and their offspring [1]. EDCs are ubiquitous environmental pollutants that are routinely detected in agricultural chemicals, industrial materials (such as heavy metals), and everyday consumer products (including plastics, cleaning agents, and personal care items) [2]. Common EDCs such as bisphenol-A (BPA), phthalates, and perfluoroalkyl and polyfluoroalkyl substances (PFAS) are able to cross the placental barrier, disrupt hormonal signaling, and provoke systemic inflammatory responses [3-5].
Moreover, growing evidence indicates that EDCs specifically impair thyroid function, prompting their designation as thyroid-disrupting chemicals (TDCs) [6]. These compounds may interfere with multiple facets of thyroid hormone regulation, including synthesis, metabolism, transport, and receptor binding [7,8]. Given the essential role of thyroid hormones in fetal brain development, even subtle disruptions in maternal-fetal thyroid homeostasis during pregnancy may result in lasting neurodevelopmental consequences [9,10].
Similarly, iodine intake, a critical factor for thyroid hormone production, constitutes a major environmental determinant of thyroid function during pregnancy [11]. Both iodine deficiency and excess have been linked to maternal thyroid dysfunction and adverse developmental outcomes in the fetus [12-14]. Notably, excessive iodine intake, often due to unregulated supplement use in iodine-sufficient populations, may increase the risk of hypothyroidism via the Wolff–Chaikoff effect [15,16].
Prenatal exposure to EDCs and iodine may affect maternal and neonatal health through both direct and indirect mechanisms. These exposures are directly associated with obstetric complications such as preeclampsia, preterm birth, and intrauterine growth restriction, and may also disrupt maternal thyroid function [17-20], leading to indirect effects. Furthermore, in utero exposure may negatively influence neonatal and early childhood outcomes, including altered thyroid function, impaired growth and neurodevelopment, and heightened susceptibility to metabolic disorders [9,21-23]. Considering these interconnected biological pathways, prenatal exposure to EDCs and iodine may increase perinatal risk through both thyroid-dependent and thyroid-independent mechanisms.
Despite these converging pathways of thyroid disruption, few studies have systematically assessed the combined effects of EDCs and dietary iodine exposure on maternal thyroid function using a prospective, longitudinal design [24,25]. To address this gap, we established the Investigating Birth and Thyroid Outcomes of Maternal-Fetal Environmental Exposures (IBM-E) cohort, a prospective study designed to evaluate the impact of combined environmental exposures—particularly EDCs and iodine—on maternal-fetal thyroid function and perinatal health. The IBM-E study is designed to assess the effects of maternal environmental exposures, including dietary iodine and EDCs, on maternal thyroid function during pregnancy. It further investigates how altered maternal-fetal thyroid status is related to pregnancy complications and perinatal outcomes and evaluates the long-term consequences of perinatal environmental exposures and thyroid dysfunction on postnatal growth and developmental trajectories in offspring.
METHODS
Study design
Participant recruitment and the inclusion criteria
The IBM-E cohort is a prospective observational study designed to investigate the association between maternal exposure to dietary iodine and/or EDCs and adverse pregnancy outcomes, including maternal thyroid dysfunction, as well as the potential effects on offspring health and development. Recruitment of pregnant women began in July 2024 and is ongoing at Severance Hospital in Seoul, Korea, through December 2027.
Pregnant women are recruited during routine prenatal visits. Eligible participants are those who are currently pregnant and willing to provide written informed consent. There is no strict gestational age limit for enrollment. However, we aim to recruit pregnant women as early as possible—preferably during the first trimester—to maximize biospecimen collection across all prenatal visits. All participants must be enrolled before delivery to ensure paired maternal and neonatal data collection and analysis. For newborn inclusion, consent is also required from their legal representative. Participants are excluded if they are pregnant with three or more fetuses, have a previous history of thyroidectomy, or are currently receiving antithyroid treatment for overt hyperthyroidism. In addition, women with a history of overt hypothyroidism who have been taking levothyroxine for more than 12 months and are still on treatment at the time of recruitment are excluded. Women with other severe comorbidities are also not eligible to participate.
Sample size
Based on an expected incidence of maternal thyroid disorder of approximately 10% during pregnancy [26,27], we estimate that at least 50 events are required for exploratory analysis and preliminary modeling of the associations between EDC exposure and thyroid dysfunction. To ensure sufficient statistical power, a minimum of 500 participants is required. The target enrollment is set at 556 mother-child pairs to allow for a 10% loss to follow-up.
Participant follow-up
Fig. 1 illustrates the timeline and procedures for participant follow-up. Maternal participants are scheduled for six visits: during the first trimester (visit 1: 11 to 13 weeks of gestation), second trimester (visit 2: 24 to 28 weeks of gestation), third trimester (visit 3: 34 to 36 weeks of gestation), at delivery (visit 4), 1 month postpartum (visit 5), and 12 to 15 months postpartum (visit 6).
Study design.
At each visit, clinical data, including vital signs (blood pressure and pulse) and anthropometric measurements (height, weight, and body mass index [BMI]), are collected from electronic medical records. EDCs are assessed through blood and urine samples obtained at the defined time points. Maternal thyroid function tests (TFTs) are conducted using blood samples, and urine samples are analyzed for the urinary iodine concentration (UIC) and creatinine levels to calculate the iodine-to-creatinine ratio. Placental tissues are collected at delivery (visit 4) (Table 1). In addition, data on pregnancy complications, such as gestational diabetes mellitus (GDM), preeclampsia, and preterm birth, as well as obstetric outcomes, including mode of delivery, gestational age at birth, and neonatal birth weight, are reviewed from electronic medical records.
Measurements of Maternal and Child Participants
Child participants are enrolled at birth and followed up at ages 1 and 12–15 months, aligning with maternal visits 5 and 6. At each visit, clinical data, including weight, height, head circumference, developmental milestones, and comorbidities, are collected. EDCs are measured in blood and urine samples collected at the designated time points. Blood samples are obtained at birth (cord blood) and again at 12 to 15 months of age (venous blood, corresponding to maternal visit 6). In addition to EDC analysis, both samples are subjected to TFTs. Urine samples are collected at three time points: immediately after birth (first-void urine), within the first month of life (aligned with maternal visit 5), and at ages 12 to 15 months. All urine samples are analyzed for EDCs, UIC, and creatinine levels to calculate the iodine-to-creatinine ratio (Table 1). Furthermore, neonatal and infant clinical outcomes are reviewed from electronic medical records, including neonatal intensive care unit admission, respiratory complications, neonatal jaundice, infections, anthropometric parameters (weight, height, head circumference), and neurodevelopmental evaluations during follow-up.
All collected biological specimens—including maternal serum and urine, paired cord serum, neonatal serum and urine, and placental tissue—are stored at −70°C until analysis to ensure sample stability and integrity.
Evaluation of iodine status
UICs are determined from spot urine samples using an inductively coupled plasma mass spectrometry system (ICP-MS, 7900 series, Agilent Technologies, Santa Clara, CA, USA). Urinary creatinine levels are analyzed using the kinetic alkaline picrate method with the Architect TBA-C16000 analyzer (Abbott, Abbott Park, IL, USA). To account for urine dilution, UIC values are normalized by urinary creatinine concentration.
Measurement of thyroid function
Thyroid function is assessed by measuring serum levels of free thyroxine (fT4), total triiodothyronine (T3), and thyroid-stimulating hormone (TSH) using a chemiluminescent microparticle immunoassay, performed with the Architect i2000 System (Abbott Korea, Seoul, Korea). The reference ranges are as follows: fT4, 0.70–1.48 ng/dL (9.01–19.05 pmol/L); T3, 80–200 ng/dL (1.23–3.08 nmol/L); and TSH, 0.38–4.94 μIU/mL. In accordance with the revised Korean Thyroid Association guidelines [11], we adopted a TSH upper limit of 4.0 mIU/L for the first trimester of pregnancy. A TSH level between 4.0 and 10.0 mIU/L with a normal fT4 level is defined as subclinical hypothyroidism. A TSH level greater than 10.0 mIU/L is defined as overt hypothyroidism, regardless of the fT4 level.
EDC measurement
This study aims to measure the concentrations of EDCs in maternal and child biological samples, specifically blood, urine, and cord blood. Three classes of compounds will be analyzed: phthalate esters and their metabolites (phthalates; n=37), environmental phenolic compounds (phenols; n=24), and PFASs (n=33) (Supplemental Table S1). The samples were prepared to measure urinary phthalate metabolites and environmental phenols using methods described in previous studies [28,29].
Phthalates and their metabolites in urine
Phthalates and alternative plasticizer metabolites are analyzed in urine samples using solid-phase extraction (SPE). Calibration standards are prepared by combining 450 μL of synthetic urine, 50 μL of standard solution, and 50 μL of internal standard. Urine samples (500 μL) are mixed with 50 μL of internal standard, followed by 10 μL β-glucuronidase and 150 μL of 1 M ammonium acetate buffer (pH 5). After vortexing, samples are incubated at 37°C for 2 hours. Hydrolyzed samples are then treated with 350 μL phosphate buffer (pH 2) and centrifuged for 5 minutes. The supernatants are loaded onto Sep-Pak cartridges (1 cc, 100 mg; Waters, Milford, MA, USA) on a Resolvex A200 system (Tecan, Männedorf, Switzerland). After washing and elution, extracts are dried under vacuum and reconstituted in 200 μL of 50% acetonitrile containing 0.1% acetic acid. Analysis is performed using ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC–MS/MS) with a Nexera LC-40 XS system (Shimadzu, Kyoto, Japan) and TQ 5500+ mass spectrometer (SCIEX, AB Sciex, Framingham, MA, USA) (Supplemental Tables S2, S3).
Environmental phenols in urine
A total of 24 environmental phenols (11 bisphenols [BPs] and 13 parabens) are selected as target analytes to assess urinary exposure, and liquid-liquid extraction is employed for their analysis. Calibration samples are prepared using 450 μL of synthetic urine, 50 μL of standard solution, and 50 μL of internal standard. For each sample, 500 μL of urine is combined with 50 μL of internal standard, 10 μL of β-glucuronidase/arylsulfatase, and 150 μL of 1 M ammonium acetate buffer (pH 5). After a 4-hour incubation at 37°C, 5 mL of ethyl acetate is added. Samples are rotated for 30 minutes and centrifuged at 5,000 rpm for 10 minutes. The supernatant is collected and combined with a second extract prepared using the same procedure. The combined organic phase is evaporated under vacuum until 100 μL remains, followed by reconstitution in 100 μL of 50% methanol, filtration, and injection. Analysis is performed using an ultra-performance liquid chromatography (UPLC) system coupled with an API 4000 triple quadrupole mass spectrometer (SCIEX) (Supplemental Tables S4, S5).
PFASs in serum
Maternal and cord serum samples are analyzed for PFASs. A total of 31 compounds, including 11 perfluorocarboxylic acids (PFCAs), seven perfluorosulfonic acids (PFSAs), nine precursors, and four alternative compounds, are selected as target analytes.
For each 200 μL serum sample, 20 μL of an internal standard mixture and 500 μL of 0.1% formic acid are added. Samples are processed using automated SPE with Strata-X-AW Tab-Less SPE cartridges (30 mg, 1 mL; Phenomenex, Torrance, CA, USA) on a Resolvex A200 system. After sample loading, cartridges are washed with water and 30% methanol, and eluted sequentially with 4 mL of methanol and 4 mL of methanol containing 0.1% ammonium hydroxide. The eluates are evaporated to dryness using a vacuum concentrator (Speed-Vac CVE-3000, EYELA, Tokyo, Japan) and reconstituted in 200 μL of acetonitrile. Quantitative analysis is conducted using a UPLC system (Agilent Infinity 1290 series, Agilent Technologies) coupled with a tandem mass spectrometer (API 4000) (Supplemental Tables S6, S7).
Quality control of EDC measurements
All analyses are conducted following validated protocols, with rigorous quality control procedures to ensure analytical reliability and accuracy. Calibration curves are established by spiking artificial urine or bovine serum with standard solutions at various concentrations, and all target compounds demonstrate excellent linearity, with coefficients of determination (r2) exceeding 0.99. Method detection limits (MDLs) are calculated based on regression analysis in accordance with National Institute for Occupational Safety and Health (NIOSH) guidelines, reflecting the lowest concentration of each compound that can be reliably detected with 99% confidence. MDLs generally range from 0.01 to 0.3 ng/mL across compounds (Supplemental Tables S8-S10). Accuracy is assessed by evaluating recovery rates at low, medium, and high concentrations, with most compounds showing recoveries within the acceptable range of 80% to 120%. Precision is determined by calculating the coefficient of variation across repeated measurements, with most results within the 15% threshold, indicating stable reproducibility. Isotopically labeled internal standards are added to all samples to enhance quantification accuracy, and quality control samples are included in each batch to continuously monitor consistency and analytical performance (Supplemental Tables S11-S13).
Statistical analysis
Statistical analyses will be performed to examine associations between urinary concentrations of 37 phthalates and 24 phenols, and serum concentrations of 33 PFASs and perinatal outcomes. Only individual compounds detected in ≥70% of all urine samples will be included in the analysis. For compounds with concentrations below the limit of quantification (LOQ), values are imputed as LOQ divided by the square root of 2 (LOQ/√2). Total concentrations are calculated by summing 18 phthalate metabolites (ΣPhthalates), eight ΣBPs, and selected PFASs, with values below the LOQ treated as zero.
Urinary concentrations of target analytes will be adjusted for specific gravity (SG) using the formula: SG-adjusted concentration=concentration×[(SG_mean−1)/(SG_ind−1)], where SG_mean and SG_ind represent the mean and individual SG values, respectively. Depending on the distribution of the exposure and outcome variables, appropriate normalization methods, such as natural log transformation, will be applied prior to statistical modeling.
To assess associations of continuous EDC exposure and UIC with thyroid function and perinatal outcomes, Pearson or Spearman correlation tests will be used based on variable distribution. These correlation analyses serve as an exploratory step. Generalized additive models with smoothing functions will be used to explore potential nonlinear relationships among EDC exposure, iodine status, and perinatal outcomes, including thyroid function. Interaction terms between EDCs and iodine status will be incorporated to assess potential combined effects. Model fit will be evaluated using the Akaike information criterion, where lower values indicate better fit.
Additionally, multivariate logistic regression models will be used to estimate adjusted odds ratios for perinatal outcomes and thyroid outcomes across categories of EDC exposure or iodine status. Covariates such as maternal age, pre-pregnancy BMI, parity, and in vitro fertilization status will be considered potential confounders. Covariate inclusion is based on statistical significance or impact on effect estimates during model selection. In cases of limited outcome events, the number of covariates will be restricted according to the events-per-variable principle. All statistical analyses will be conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA) and SPSS version 18.0 (IBM, Chicago, IL, USA), with statistical significance defined as a two-tailed P<0.05.
Ethics approval and consent to participate
The study protocol was approved by the ethics committee of Severance Hospital (IRB No. 4-2017-0348), and all mother-child pair participants provided written informed consent.
RESULTS
As of April 2025, 193 pregnant women have been enrolled in this ongoing prospective study, which began in 2024. The median maternal age was 35 years (range, 24 to 48), and 53.4% were nulliparous. Multiple pregnancies accounted for 17.6% of cases. Chronic hypertension was present in 3.1% of participants. Pre-GDM was identified in 1.0% (n=2) of the participants, and both cases were managed with insulin therapy. Pregnancy-related complications included preeclampsia, which occurred in 11.4% of participants, and GDM, which was diagnosed in 8.3% (n=16); among those with GDM, six required insulin treatment (Table 2).
Maternal Characteristics in the Preliminary Data (n=193)
Thyroid dysfunction—defined as hyperthyroidism, hypothyroidism, or subclinical hypothyroidism (excluding thyroid nodules or thyroiditis)—was observed in 15.0% (n=29) of participants. One participant with hyperthyroidism was treated with antithyroid medication, and all five participants with overt hypothyroidism received levothyroxine. Among the 16 participants with subclinical hypothyroidism, six received short-term levothyroxine therapy during early pregnancy, nine were treated throughout pregnancy, and one did not receive any medication.
The median gestational age at delivery was 38.2 weeks (range, 18.4 to 40.6), and 23.8% of the participants experienced preterm birth. Cesarean section was performed in 86.0% of the cases. Placental pathology was observed in 42.0% of cases, with maternal vascular underperfusion identified in 24.7%. Among 229 neonates, the median birthweight was 2,880 g (range, 196 to 4,180), and 53.7% were male. Small for gestational age was observed in 16.6% of neonates, and 24.0% were admitted to the neonatal intensive care unit. Among the neonates, 14.0% experienced at least one complication, including respiratory distress syndrome, sepsis, or neonatal death (Table 3).
Delivery and Neonatal Outcomes
DISCUSSION
Exposure to EDCs during pregnancy has become a significant public health concern owing to their potential to disrupt maternal metabolic regulation, placental function, and fetal development. Common EDCs, such as phthalates, BPA, and PFAS, have been linked to adverse pregnancy outcomes, including GDM, preeclampsia, and preterm birth [18,30,31]. These effects are mediated through endocrine dysregulation, systemic inflammation, and placental insufficiency [5,18,32]. Mechanistic studies suggest that EDCs affect trophoblast proliferation, angiogenesis, and immune signaling via oxidative stress, DNA methylation, and peroxisome proliferator-activated receptor-γ modulation, thereby impairing placental development [33-35]. Consequently, maternal and fetal health may be compromised.
Moreover, EDCs are increasingly recognized as TDCs because they interfere with thyroid hormone synthesis, metabolism, and action [6-8]. Given the critical role of thyroid hormones in fetal brain development, particularly during early gestation when the fetus relies on maternal thyroid hormones, disrupted maternal-fetal thyroid homeostasis may result in enduring and long-lasting neurodevelopmental consequences [9,10]. Similarly, excessive or deficient intake of iodine—a critical nutrient for thyroid hormone biosynthesis—may independently or synergistically exacerbate thyroid dysfunction during pregnancy [36,37]. Iodine excess induces transient hypothyroidism through the Wolff–Chaikoff effect, particularly in populations with preexisting thyroid autoimmunity or immature fetal thyroid systems [15,16]. Conversely, iodine deficiency remains a global concern and has been associated with neurocognitive impairment and cretinism in severe cases [38,39]. The dual risk posed by insufficient and excessive iodine intake highlights the importance of precise evaluation of iodine status during gestation.
Despite these concerns, previous studies have predominantly relied on cross-sectional or trimester-specific designs, which limit the ability to assess temporal dynamics and causality [40,41]. To overcome these limitations, the IBM-E cohort was established as a prospective, longitudinal study designed to evaluate the impacts of maternal exposure to nutritional (e.g., iodine) and non-nutritional (e.g., EDCs) environmental factors on maternal-fetal thyroid function and perinatal outcomes.
The IBM-E study builds upon findings from the prior Ideal Breast Milk (IBM) cohort, which included high-risk pregnancies at a tertiary hospital and evaluated dietary iodine intake and its association with thyroid function and obstetrical outcomes [42,43]. The IBM cohort was a prospective birth cohort of 442 pregnant women recruited at Seoul National University Hospital between June 2016 and December 2019. In that study, despite widespread excessive iodine intake due to traditional dietary practices such as postpartum seaweed soup consumption, maternal iodine status showed no significant association with maternal or neonatal thyroid dysfunction or with adverse birth outcomes [44]. These findings were inconsistent with earlier studies in iodine-replete populations, highlighting the need for validation in broader and more diverse cohorts [45-47]. Furthermore, a secondary analysis in the IBM cohort focused on twin pregnancies found that maternal PFAS levels were linked to vascular malperfusion and placental asymmetry, emphasizing the need to further assess EDC effects in vulnerable subpopulations [29].
The IBM-E cohort addresses these needs by incorporating serial biospecimen collection at multiple predefined time points during pregnancy and postpartum, allowing for time-resolved exposure profiling and identification of critical windows of susceptibility. Integration of maternal, placental, and neonatal biospecimens with electronic medical records supports comprehensive evaluation of endocrine and metabolic phenotypes. By concurrently evaluating UICs and EDC metabolites, the IBM-E study enables the characterization of combined nutritional-toxicant exposure profiles and their associations with thyroid hormone levels.
An additional strength of the IBM-E cohort is its potential for integrative analysis with the original IBM cohort [42]. By pooling data from both cohorts, we anticipate increased statistical power and the ability to validate key exposure—outcome associations, particularly regarding iodine and EDC interactions with thyroid function. This approach also facilitates exploration of gene–environment interactions and epigenetic mechanisms underlying the observed clinical phenotypes.
Although the IBM-E cohort is based at a single tertiary center, it employs standardized protocols and state-of-the-art analytical platforms, such as UHPLC–MS/MS, enabling precise quantification of trace-level environmental toxicants [48]. While generalizability may be limited, the high fidelity of clinical and biochemical data collection enhances internal validity. Future directions include extending follow-up into childhood to assess long-term developmental outcomes and incorporating multiomics analyses to elucidate biological pathways linking environmental exposure with health trajectories.
The IBM-E cohort represents a methodologically rigorous platform to investigate the complex interplay between environmental exposures, thyroid homeostasis, and perinatal health. These findings may inform clinical guidelines, public health policies, and individualized strategies for risk mitigation in vulnerable pregnant populations.
Supplementary Material
Supplemental Table S1.
The Abbreviation and Nomenclature of Phthalates, Phenols, and PFASs
Supplemental Table S2.
UPLC-MS/MS Conditions for Phthalates and Alternative Plasticizers Metabolome Analysis in Human Urine
Supplemental Table S3.
Multiple Reaction Monitoring Parameters of Mass Spectrometer for Phthalates and Alternative Plasticizers Metabolome Analysis in Human Urine
Supplemental Table S4.
UPLC-MS/MS Conditions for Environmental Phenols Analysis in Human Urine
Supplemental Table S5.
Multiple Reaction Monitoring Parameters of Mass Spectrometer for Environmental Phenols Analysis in Human Urine
Supplemental Table S6.
UPLC-MS/MS Conditions for PFASs Analysis in Human Serum
Supplemental Table S7.
Multiple Reaction Monitoring Parameters of Mass Spectrometer for PFASs Analysis in Human Serum
Supplemental Table S8.
MDL, LOQ, and Linearity of the Phthalates and Alternative Plasticizers Metabolome Analysis Method in Human Urine through Analysis Method Validation
Supplemental Table S9.
MDL, LOQ, and Linearity of the Environmental Phenols Analysis Method in Human Urine through Analysis Method Validation
Supplemental Table S10.
MDL, LOQ, and Linearity of the PFASs Analysis Method in Human Serum through Analysis Method Validation
Supplemental Table S11.
Precision and Accuracy of the Phthalates and Alternative Plasticizers Metabolome Analysis Method in Human Urine through Analysis Method Validation
Supplemental Table S12.
Precision and Accuracy of the Environmental Phenols Analysis Method in Human Urine through Analysis Method Validation
Supplemental Table S13.
Precision and Accuracy of the PFASs Analysis Method in Human Serum through Analysis Method Validation
Notes
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
ACKNOWLEDGMENTS
This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2025-02272995).
AUTHOR CONTRIBUTIONS
Conception or design: Y.J.J., J.E.S, J.Y., S.S., D.Y.S., M.G., Y.K., J.H.L. Acquisition, analysis, or interpretation of data: Y. J.J., J.E.S., J.Y., S.K., H.K., S.S., D.Y.S., M.G., Y.K., J.H.L. Drafting the work or revising: Y.J.J., J.E.S., J.Y., M.G., Y.K., J.H.L. Final approval of the manuscript: Y.J.J., J.E.S., D.Y.S., Y.K., J.H.L.